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Abstract
Background: PTX is one of the most widely used drug in oncology due to its high efficacy against
solid tumors and several hematological cancers. PTX is administered in a formulation containing
1:1 Cremophor® EL (polyethoxylated castor oil) and ethanol, often responsible for toxic effects. Its
encapsulation in colloidal delivery systems would gain an improved targeting to cancer cells,
reducing the dose and frequency of administration.
Methods: In this paper PTX was loaded in PLGA NS. The activity of PTX-NS was assessed in vitro
against thyroid, breast and bladder cancer cell lines in cultures. Cell growth was evaluated by MTS
assay, intracellular NS uptake was performed using coumarin-6 labelled NS and the amount of
intracellular PTX was measured by HPLC.
Results: NS loaded with 3% PTX (w/w) had a mean size < 250 nm and a polydispersity index of
0.4 after freeze-drying with 0.5% HP-Cyd as cryoprotector. PTX encapsulation efficiency was 30%
and NS showed a prolonged drug release in vitro. An increase of the cytotoxic effect of PTX-NS
was observed with respect to free PTX in all cell lines tested.
Conclusion: These findings suggest that the greater biological effect of PTX-NS could be due to
higher uptake of the drug inside the cells as shown by intracellular NS uptake and cell accumulation
studies.
Background
PTX is a taxane plant product derived from the bark of the
pacific yew tree Taxus brevifolia. Unlike other tubulin
binding agents, such as Vinca alkaloids, which induce the
disassembly of microtubules, PTX promotes the stabiliza-
tion of tubulin polymerization [1]. The microtubule
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dysfunctional with a consequent cell cycle arrest at the
G2/M phase and inhibition of mitosis [2].
PTX has a significant antineoplastic activity in solid tumor
and it is currently approved by both the FDA and the
EMEA for the treatment of non-small cell lung cancer,
breast cancer, ovarian cancer and AIDS-related Kaposi's
sarcoma. In addition PTX is also successfully used, either
as single agent and in combination with other antineo-
plastic agents, in the treatment of thyroid, bladder, head
and neck cancers [3-8].
However, the clinical application of PTX is limited by its
low therapeutic index and its low solubility in water [9].
Accordingly, standard formulation of PTX (Taxol®)
requires the use of solvents, such as Cremophor® EL (poly-
oxyethylated castor oil) and dehydrated alcohol, which
contribute to most of the toxicity commonly associated
with PTX-based therapy [10]. For these reasons, alterna-
tive dosage forms without Cremophor have been pro-
posed, including parenteral emulsions, liposomes,
microspheres, cyclodextrin complexes and NP [9,11].
The most interesting approach for PTX drug delivery
appears the encapsulation in NP made of biodegradable
polymers, such as PLGA or PLA. According to the process
in NP preparation, NS or nanocapsules can be obtained.
Nanocapsules are vesicular systems in which a drug is con-
fined inside a cavity surrounded by a polymeric mem-
brane whereas NS are matrix systems in which a drug is
dispersed through the particles [12]. The encapsulation in
NP affects in PTX tissue distribution to cancer cells with a
consequent increase of both efficacy and safety [9,13,14].
Furthermore NP, for their small size, can escape from the
reticulo-endothelial system and accumulate for passive
diffusion inside the tumor; this effect is enhanced by the
high vascular permeability and the retention capability
typical of the tumor tissue [15]. As a consequence, the
higher retention time of intracellular PTX may reduce the
number of administrations with a significant improve-
ment of the patient's compliance.
The clinical application of NP-based drug delivery sys-
tems, is often limited by the physical (aggregation/particle
fusion) and/or chemical instability of the colloidal sus-
pension (hydrolysis of polymer, drug leakage, chemical
reactivity of drugs), which become more evident during
long term storage [16]. The most efficient technique to
improve the stability of these suspension is to remove
water, usually by freeze-drying. However, this process gen-
erates a variable degree of stress to NP so that protectors
are usually added to the formulation [17]. Such protec-
tion is usually achieved by adding inert additives, as sug-
ars.
We have recently described the preparation and techno-
logical characterization of cryoprotected NS formulations
for PTX controlled delivery [18]. One of these formula-
tions, containing HP-Cyd as a cryoprotector, has been fur-
ther characterized in the present study describing its in
vitro activity against the human ARO ATC cell line. Even
if ATC is a rare carcinoma, it is one of the most aggressive
solid tumors with a mean survival of only six months.
ATC are always unresponsive to radioiodine [19] and are
therefore treated with a multimodality approach includ-
ing surgery, radiotherapy or radio-chemotherapy and
chemotherapy. Among the newer agent used for chemo-
therapy, PTX appears the only agent effective on ATC;
however PTX is not able to modify in a significant manner
the clinical course of such patients [3,20]. The results of
our study suggest that the incorporation of PTX in NS
enhances its cytotoxic effect on human ARO cells possibly
due to higher uptake of the drug inside the cells. These
effects have also been confirmed in other two model of
human carcinomas, the MDA MB 231 breast carcinoma
cells and the RT112 bladder carcinoma cells.
Methods
Materials
The following products were commercially available:
Resomer® RG 502 H (50:50 PLGA) (Boehringer Ingelheim
GmbH, Germany); Tween 80®, PTX, PI and Coumarin 6
(Sigma-Aldrich Chimica Srl, Milan, Italy); HP-Cyd
(Cyclolab, Budapest, Hungary); RPMI 1640, DMEM, PBS,
glutamine, penicillin-streptomycin and FBS (GIBCO,
Grand Island, NY, USA); MTS assay (Promega Co., Madi-
son, WI, USA).
ARO cell line was kindly provided by dr. Paolo Vigneri,
Department of Biomedical Sciences, University of Cata-
nia, Italy; MDA MB231 and RT112 cell line were pur-
chased from the ATCC (American Tissue Culture
Collection, Rockville, MD, USA).
All other chemicals and solvents were of analytical reagent
grade. De-ionized double-distilled water was used
throughout the study.
Preparation of PTX-loaded NS and coumarin-loaded NS
PLGA NS were prepared by solvent displacement followed
by polymer deposition [18]. PTX (3% w/w) and 75 mg
PLGA NS were dissolved in 20 ml acetone. The organic
phase was poured dropwise (0.5 ml/min), under mag-
netic stirring, into 40 ml of a water/ethanol solution (1:1,
v/v) containing 0.5% (w/v) Tween 80 to obtain a milky
colloidal suspension. The organic solvent was then evap-
orated off under high vacuum at 40°C. The different for-
mulations were purified from untrapped PTX and
unadsorbed surfactant by means of centrifugation (15000
× g) for 1 h at 5°C, using a Beckman (Fullerton, CA) J2-21Page 2 of 11
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fixed-angle rotor. The supernatants were discarded and
the pellets were resuspended in 50 ml of water, then cen-
trifuged using the same conditions described above. The
entire operation was repeated 3 times. After final washing,
the NS were resuspended in 5 ml of filtered water (0.22-
μm Sartorius membrane filters) in the presence of 5% of
HP-Cyd as a cryoprotector [18] and freeze-dried. Freeze-
dried NS were resuspended with filtered water and were
characterized for size distribution, surface chemistry and
technological parameters. For the in vitro studies, freeze-
dried NS were resuspended in RPMI 1640 supplemented
with 10% heat-inactivated fetal calf serum, 2 mM L-
glutamine and 100 U/ml penicillin-streptomycin.
Coumarin 6-loaded NS were prepared similarly for the
fluorescent microscopic studies. The polymer solution
contained 0.05% (w/v) coumarin-6 as fluorescent marker
instead of PTX.
Physico-chemical, morphological, and technological 
characterization of PTX-NS
SEM was performed to evaluate the surface morphology
of NS using a SEM XL-30 (Philips, Eindhoven, the Nether-
lands). PTX-NS freeze-dried in the presence and in the
absence of the cryoprotector were fixed by means of bi-
adhesive tape on a glass disk applied to an aluminum stub
(TAAB, Laboratories Equipment, Berks, UK) and evapo-
rated under vacuum overnight. Before the SEM analysis
the samples were metallized under argon atmosphere to
10 nm gold palladium thickness (EMITECH-K550 Sputter
Coater, Houston, Tex., USA).
NS mean size was determined by PCS using a Zetamaster
instrument (Malvern Instruments Ltd, Worcs, England). A
solid state laser was used as the light source, with a nomi-
nal power of 4.5 mW and a maximum output of 5 mW at
670 nm. The photon correlation spectroscopy measure-
ments were carried out at a scattering angle of 90°. To
obtain the mean diameter and polydispersity index of the
colloidal suspensions, a third-order cumulant fitting cor-
relation function was performed by a Malvern PCS submi-
cron particle analyzer. For each sample 100 μl were
suitably diluted with 2 ml of filtered water to avoid multi-
scattering phenomena and placed in a quartz cuvette. The
size analysis consisted of 30 measurements per sample,
and the results are expressed as mean size ± SD. The fol-
lowing instrument parameters were set: average index of
refraction at 1.330, average viscosity at 1.00, and the die-
lectric constant equal to 79.
Zeta potential distribution was measured with a Zetamas-
ter particle electrophoresis analyzer setup equipped with a
5-mW HeNe laser (633 nm). Limits of ζ-potential ranged
from -120 to 120 Volt. Parameters were set as follows:
strobe delay -1.00, on time 200.00, off time 1.00. A
Smoluchowsky constant F(Ka) of 1.5 was used to achieve
ζ-potential values from the electrophoretic mobility data.
One hundred μl of each sample were suitably diluted with
20 ml of filtered water.
To assess the drug concentration in the NS, pellets
obtained from freeze-dried NS were dissolved in 1 ml of
acetonitrile, filtered through 0.45-μm nylon membrane
filters (Whatman) and subjected to HPLC analysis Encap-
sulation efficiency was calculated as the mass ratio of the
entrapped drug in NS to the amount used in their prepa-
ration.
The in vitro release studies were carried out as described
by Mu and Feng [21]. Aliquots of 50 mg of freeze-dried
and cryoprotected PTX-loaded NS were placed in a screw-
capped tube and suspended in 5 ml of isotonic PBS pH
7.4. The tube was placed in a water bath at 37 ± 0.5°C
under magnetic stirring. At fixed time intervals, three
tubes for each batch were removed and centrifuged at
14,000 g for 1 h. The supernatants were extracted with 3 ×
5 ml-aliquots of dichloromethane. The solvent aliquots
were pooled, evaporated under nitrogen and the residue
was dissolved in 500 μl of acetonitrile. The resulting solu-
tions were analyzed by HPLC to determine the drug con-
centration. The pellets were resuspended in 5 ml of fresh
PBS and then replaced in the water bath.
The efficiency of the extraction process was evaluated in
triplicate using 5 ml of PBS solutions containing different
known concentrations of pure PTX and submitted to the
same extraction procedure described above, and was
found to be 93.9 ± 0.4%.
Cell lines
ARO human ATC cells, MDA MB 231 human breast carci-
noma cells and RT112 human bladder carcinoma cells
were grown at 37°C in a 5% CO2 atmosphere in RPMI
1640 supplemented with 10% FBS, 2 mM L-glutamine
and 100 U/ml penicillin-streptomycin.
In vitro particle cell uptake: fluorescent microscopic 
studies
ARO cells were seeded in 24-well glass slides. At 80% con-
fluency, medium was replaced with 1 ml of coumarin-6
loaded particle suspension (250 μg/ml). After 2 h of incu-
bation, cells were fixed with 70% ethanol solution and
kept at 37°C for 20 min. Subsequently PBS was used to
wash wells for three times and 1 μg/ml PI was added to
stain cell nucleus for 30–40 min. PI was washed three
times using PBS and the glass slides were observed by flu-
orescence microscopy. Coumarin-6-loaded particles and
PI-staining cell nucleus showed green colour and red col-
our respectively.Page 3 of 11
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Cell viability was evaluated using the MTS colorimetric
assay based on the reduction of a tetrazolium compound
(MTS) to a colored formazan product that is then meas-
ured at 490 nm; absorbance is directly proportional to the
number of living cells in the culture. Briefly, cells were
seeded in 96-well plates at 5 × 103 cells/200 μl/well and
allowed to adhere to the plate overnight. The next day the
cells were treated with free PTX or PTX-NS at a concentra-
tion depending on cell type according to its growth curve.
Dilutions were made using the culture medium from
stock solution of the drug in ethanol or NS suspensions,
respectively. After incubation, the culture medium was
aspirated and cells were washed with PBS (pH 7.4); 100 μl
of fresh culture medium without drug and 20 μl of MTS
were added to each well and the cells were incubated for
3 h. The plates were read on a Microplate Reader (Synergy
HT, BIO-TEK). Survival was expressed as the percentage of
viable cells in treated samples relative to not treated con-
trol cells. All the experiments were repeated three times in
triplicate.
Accumulation studies of PTX-NS
Cells were seeded in 6-well plates at 1 × 105 cells/4 ml/
well and allowed to adhere to the plate overnight. After 24
h cells were treated with 2.13 and 4.27 μg/ml of free PTX
or PTX NS. After 48 h of incubation, the culture medium
was collected and frozen at -80°C (sample A). Adherent
cell line were trypsinized; trypsin was inactivated with
medium and the suspension was stored at -80°C (sample
B).
Sample A containing the culture medium with dead cells
was treated as follows: 2.5 ml was incubated with 1.25 ml
of ZnSO4 (4% w/v in H2O/CH3OH 70/30) to precipitate
proteins. The obtained suspension was vortexed for 5
min, stored at 4°C for 10 min to permit the complete pro-
teins denaturation and then centrifuged at 4000 rpm for
15 min. The supernatant was filtered through 0.2 μm
nylon membrane filters (Whatman) and subjected to
HPLC analysis to assess the drug concentration (C,
amount of intracellular PTX not bound to microtubules
and released from NS in the medium). The pellet was
treated with 500 μl of CH3CN (that was used to break NS
and to extract PTX) and centrifuged at 4,000 rpm for 15
min. This procedure was repeated three times to ensure
the complete extraction of the drug. The resulting super-
natants were dissolved and dried under reduced pressure.
The obtained solid samples were dissolved in 500 μl of
CH3CN, filtered through 0.2 μm nylon membrane filters
and analyzed by HPLC to evaluate the amount of PTX not
released from NS (B).
Sample B, containing the culture medium with viable cells
was treated as follows: cells treated with trypsin were cen-
trifuged at 4,000 rpm for 15 min, the supernatant was
eliminated and the pellet was treated with ZnSO4 as above
described. The solid sample was dissolved with 500 μl of
CH3CN, filtered and analyzed by HPLC to evaluate the
amount of PTX not bound to microtubules (D). The active
fraction of PTX (X, bound to tubulin), was calculated as
the difference between the initial amount (A) and the
total of inactive drug (B, C, D) [X = A - (B + C + D)].
HPLC analysis
HPLC analysis was performed at room temperature using
a 1050 Hewlett Packard apparatus on a 5 μm HP Hypersil
ODS cartridge (125 × 4 mm i.d.) equipped with a 5 μm
HP Hypersil 100 RP-18 guard cartridge (4 × 4 mm i.d.)
and eluted isocratically with acetonitrile/water (60/40, v/
v). Flow rate was set at 1 ml/min and UV detection was
made at 230 nm. The linear regression coefficient, deter-
mined in the range 0.33–33 μg/ml, was 0.9992 (n = 6).
The method sensitivity was 3 ng/ml (signal to noise ratio,
3:1).
Statistical analysis
All data were analyzed by using Student t-test. A p value
less than 0.05 was accepted as statistically significant. All
data analyses were done using Minitab statistical software
(Origin Lab ver. 7.0, ORIGINLAB Co., Northampton, MA,
USA).
Results
The morphological characteristics of PTX NS freeze-dried
in the presence or absence of the cryoprotector HP-Cyd
have been examined by SEM (Figure 1). Before freeze-dry-
ing, the presence of HP-Cyd did not influence the mean
size and the homogeneity of the NS since they maintained
a smooth and spherical surface (Figures 1A and 1C). By
contrast, the absence of cryoprotector caused evident signs
of aggregation, that hindered the following resuspension
(Figure 1B); the presence of HP-Cyd prevented the aggre-
gation of NS (Figure 1D). These results confirm therefore
the importance of a cryoprotector to maintain the phys-
ico-chemical parameters of a colloidal suspension for
long term storage.
Mean particle size, polydispersity index, Zeta potential,
and encapsulation efficiency of PTX-NS with HP-Cyd
before and after freeze-drying are shown in Table 1. All the
parameters were slightly modified after freeze-drying but
without any significant difference (data not shown); with
respect to empty NS, PTX loading did not altered them in
a significant manner. The in vitro PTX release from PLGA
NS displayed a rapid leakage during the first 2 days and a
constant release which was completed within 15 days
(Figure 2).Page 4 of 11
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cells
We first studied the ability of ARO cells to uptake the
PLGA NS. Cells were incubated for 2 h with PLGA NS
loaded with the fluorescent (FITC) probe Coumarin-6
and then examined by fluorescent microscopy. Nuclei
were stained with PI. No fluorescence was detected from
cells not exposed to Coumarin-6 proving the absence of
cell or NS auto-fluorescence (data not shown). The fluo-
rescence of Coumarin-6 loaded PLGA NS (green) was
closely located around the nuclei (red) indicating a signif-
icant accumulation of PLGA NS by ARO cells (Figure 3).
The cytotoxicity and subsequent therapeutic potential of
PTX-NS was thereafter evaluated by incubating ARO cells
with increasing concentrations of free or NS-loaded PTX
(1.28 to 4.27 μg/ml) for 24 and 48 h. Cell growth was
then assessed by using the MTS assay. Empty PLGA NS
were not cytotoxic to cells at all concentrations and time
interval tested (data not shown). PTX reduced cell growth
in a significant manner (p < 0.01, Student's t test) by
approximately 40% and 70% after 24 and 48 h of expo-
sure, respectively; a clear dose-response relationship was
not observed in both experimental conditions (Figure 4A
and 4B). The two formulations (free PTX and PTX-NS)
had a comparable cytotoxic effect after 24 h of exposure
whereas, after 48 h, PTX-NS was more potent than free
PTX starting at a concentration of 2.13 μg/ml (p < 0.05).
Interestingly, we observed that PTX-NS was also capable
to induce a significant (p < 0.05) decrease of cell growth
(approximately 20%) under the experimental conditions
(2-h incubation and PTX concentrations below 1.0 μg/
ml) in which free PTX was not active (Figure 4C).
Finally, in order to investigate whether the observed
higher cytotoxic effect of PTX-NS in respect to free PTX
was due to higher intracellular uptake of PTX, the amount
In vitro release of PTX-NSFigu e 2
In vitro release of PTX-NS. PTX 3% loaded NS in pH 7.4 
phosphate buffer solution, at 37°C for 360 h. Data are 
expressed as the mean ± SD of five separate experiments.
0
10
20
30
40
50
60
70
80
90
0 40 80 120 160 200 240 280 320 360
time (h)
%
 
re
le
as
e
―■― PTX-NS
Table 1: Mean particle size, size distribution (polidispersivity index, PDI), Zeta potential and encapsulation efficiency (EE) of empty 
PLGA NS and PTX-NS before and after freeze-drying.
Freeze-drying Mean size (nm) PDI Zeta potential (mV) % E.E.
PLGA NS before 292.20 ± 72.50 0.385 ± 0.144 -5. 20 ± 0.10 -
after 386.76 ± 45.50 0.340 ± 0.150 -4. 60 ± 0.20
PTX-NS before 192.00 ± 18.40 0.296 ± 0.071 -6.20 ± 0.20 35.59 ± 2.53
after 286.76 ± 45.50 0.340 ± 0.089 -5.10 ± 0.10
Data are expressed as the mean ± SD of five separate experiments.
Scanning electron microscopy of 3% PTX-NSFigure 1
Scanning electron microscopy of 3% PTX-NS. Scan-
ning electron micrographs of PTX-NS without cryoprotector 
(1A), freeze-dried without cryoprotector (1B), with the addi-
tion of HP-Cyd as a cryoprotector (1C) and freeze-dried 
with HP-Cyd (1D). Magnifications: 1 μm (A and D), 0.5 μm 
(B), 5μm (C).Page 5 of 11
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measured by HPLC (accumulation studies). For this pur-
pose, ARO cells were exposed to either free PTX or PTX-NS
at concentrations able to inhibit cell growth in a signifi-
cant manner (2.13 μg/ml and 4.27 μg/ml); at the end of
incubation (48 h) cells were processed and active PTX
quantized. The percentage of active PTX was approxi-
mately 90% of the loaded dose for PTX-NS and only 60 to
70% for free PTX (at 4.27 and 2.13 μg/ml, respectively).
Accordingly, the absolute amount of PTX bound to tubu-
lin was higher after incubation with PTX-NS with a 2-fold
difference in respect to the free PTX at the concentration
of 4.27 μg/ml (Figure 5).
3. Biological activity of PTX-NS in other cell lines
To prove that our findings were not confined to thyroid
cells, the cytotoxic activity PTX-NS was assessed against
other cell lines derived from tumor types in which PTX is
effective, such as breast and bladder carcinomas.
Data obtained in MDA MB 231 breast cancer cells are
shown in Figure 6 whereas data from RT112 bladder can-
cer cells are shown in Figure 7 (panels A = 24 h, panels B
= 48 h). Empty PLGA NS was not toxic to cells even at the
higher concentrations (data not shown) and cell growth
decreased significantly even at the lower concentration of
free PTX tested (0.1 μg/ml) in a time dependent manner
but without a clear dose-response relationship. PTX-NS
had a more powerful activity at all doses but reached a sta-
tistical significance at the concentration of 1 μg/ml.
Among cells, RT112 bladder cancer cell line was the most
responsive to PTX with a 80% maximal inhibition of cell
growth.
Discussion
PTX is one of the most interesting drugs currently availa-
ble for cancer therapy. Its primary place in therapy is in
the treatment of breast, ovarian and lung (non-small-cell)
cancers and AIDS-related Kaposi's sarcoma, but it is also
used in other malignancies, including ATC, bladder, head
and neck cancers [3-8]. However the clinical utility of PTX
is limited by its poor water solubility and therefore sys-
temic administration of this drug relies upon concomitant
use of Cremophor EL® to produce an adequately soluble
formulation. Unfortunately, Cremophor EL® use is also
associated with patient toxicity as it is not well tolerated
and leads to hypersensitivity reactions in some individu-
als. To overcome these difficulties, clinicians have
attempted to prolong infusion schedules or use corticos-
teroids and anti-histaminic drugs as a part of a pre-medi-
cation regimen. However, to improve the efficacy of PTX
in anti-cancer therapy, a potential solution must involve
reformulation of the drug into better-tolerated and selec-
tively delivered vehicles. Accordingly, a number of strate-
gies to develop alternative formulations of PTX are in
progress, including the use of albumin NP, pro-drugs
(Xyotax and Taxoprexin), co-solvents (Genexol PM),
emulsions, liposomes and microspheres [22].
Among these new drug delivery systems, polymeric NP are
considered the interesting carriers for PTX as well as other
anticancer agents. In fact NP are easily prepared with bio-
degradable polymers (as PLGA) and are highly stable in
biological fluids and during storage [9,18]. In addition
these systems are known to distribute to tumor sites to a
great extent due to a passive targeting phenomenon which
takes advantage of the enhanced permeability and reten-
tion effect [23]. The hyper-permeability of tumor tissue
vasculature allows the extravasations of NP within tumor
interstitium and the concomitant lack of tumor lymphatic
drainage in the tumor bed, resulting in NP accumulation.
As a consequence NP are able to increase the concentra-
tion of the carried chemotherapeutic agent within the
tumor tissue [23]. For instance, FDA has recently
approved Ambraxane as the first protein-stabilized NP
formulation of PTX for its significantly improved cyto-
toxic activity in respect to the standard PTX formulation.
The most common drawback of clinical application of NP
is their thermodynamic instability of their suspension
Intracellular distribution of NS in ARO cellsFigur  3
Intracellular distribution of NS in ARO cells. ARO 
cells were incubated for 2 h with PLGA NS loaded with the 
fluorescent coumarin-6 probe and analyzed by fluorescent 
microscopy. Nuclei were stained with PI and are visible in 
red (1A). The uptake of coumarin-6-loaded NS is visible in 
green (1B). Figure 1C displays an overlaying images obtained 
combining the FITC and the PI filters. A representation of 
two experiments is shown. Magnification: 63 ×Page 6 of 11
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Cytotoxicity of free PTX and PTX-NS in ARO cellsFigure 4
Cytotoxicity of free PTX and PTX-NS in ARO cells. ARO cells were treated with increasing concentrations (0.2 – 4.27 
μg/ml) of either free or NS-loaded PTX for different times (4A = 24 h, 4B = 48 h, 4C = 2 h). Cell viability was assessed by the 
MTS assay. Data are expressed as % of viable cells (mean ± SD of three separate experiments, each performed in triplicate) 
exposed to PTX in respect to untreated controls. • free PTX vs. PTX-NS, *treated vs. not treated •*p < 0.05 ••**p < 0.01
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technique. This step, however, can negatively affect the
colloidal system and therefore an adjuvant, commonly
called cryoprotector, is usually added to the solution with
the aim to preserve the morphology of colloidal particles
and their following reconstitution in water [17]. We have
previously described the encapsulation of PTX in NS by a
solvent displacement followed by polymer deposition
method to evaluate the effect of different polymers and
cryoprotectors on particle diameter, size distribution and
drug loading capacity [18]. We found that this method
produces stable PTX-NS which can be stored for a long
period without loosing their physical and chemical char-
acteristics upon reconstitution [18]. A colloidal NS sus-
pension containing PLGA and HP-Cyd, has been further
characterized in the present study. PLGA has been chosen
because it is one of the most suitable FDA approved bio-
degradable polymer; HP-Cyd, on the other hand, is a very
effective cryoprotector [18] which is able to maintain
physical characteristics of the colloidal suspension as
demonstrated by the SEM studies conducted herein.
The used PLGA produced small NS (~300 nm) with a low
polydispersity index, indicating a homogeneous size dis-
tribution. After freeze-drying, NS size slightly increased
(to about 400 nm), most probably because of the absorp-
tion of the cryoprotector. PTX-loaded NS showed a
smaller size than unloaded particles; this effect can be due
to a simultaneous precipitation of polymer and PTX in the
aqueous phase, with a consequent reduction of the
amount of polymer per particle. Accordingly, also the
polydispersity index and the zeta potential values were
lower for PTX-NS in respect to the unloaded NS. It is
important to underline the close relationship between NS
size and biological effect of PTX since smaller particles are
able to better pass through the leaky endothelial cells [23].
The amount of PTX released from the NS in which it is
Cytotoxicity of free PTX and PTX-NS in MDA MB231 cellsFigure 6
Cytotoxicity of free PTX and PTX-NS in MDA 
MB231 cells. MDA MB231 cells were treated with increas-
ing concentrations (0.1 – 2.0 μg/ml) of either free PTX or 
PTX-NS for 24 (6A) or 48 (6B) h and cell viability assessed by 
the MTS assay. Data are expressed as % of viable cells (mean 
± SD of three separate experiments, each performed in trip-
licate) exposed to PTX in respect to untreated controls. • 
free PTX vs. PTX-NS, *treated vs. not treated *p < 0.05 ••**p 
< 0.01
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Accumulation of PTX in ARO cellsFig re 5
Accumulation of PTX in ARO cells. ARO cells were 
incubated for 48 h with 2.13 or 4.27 μg/ml of either free PTX 
or PTX-NS. The amount of active PTX present in the cells 
was analyzed by HPLC. Data are expressed as mean ± SD of 
three replicates.
0
2
4
6
8
10
12
14
16
18
4.27 2.13 μg/ml 
Free PTX PTX-NS 
a
ct
iv
e 
PT
X
 (μ
g)Page 8 of 11
(page number not for citation purposes)
BMC Cancer 2008, 8:212 http://www.biomedcentral.com/1471-2407/8/212uniformly embedded was approximately 75% of the
loaded dose. Such release generally occurs by diffusion or
erosion of the matrix and depends on different parameters
(for example particle size and/or molecular weight of the
polymer). The release behaviour of the formulation used
in this study showed a biphasic pattern, with an initial rel-
evant burst effect (possibly due to the diffusion of the co-
precipitated drug from NS surface), followed by a slower
and more constant release. Similar patterns have been
described for the release of PTX from other polymeric sys-
tems [9,11,24].
An ATC cell line (ARO cells) was used in this study as the
main model to determine the anti-tumor activity of PTX,
either free or incorporated in NS. Some data have also
been replicated on two other cell lines derived of tumor
types in which PTX is effective, namely breast cancer
(MDA MB 231 cells) and bladder carcinoma (RT112 cells)
indicating that our findings are not confined to thyroid
cells. Even if ATC is a rare carcinoma, it is one of the most
aggressive and lethal solid tumors known to affect
humans with a median survival of 4 to 12 months from
the time of diagnosis. Because > 50% of ATC patients have
metastastic disease at presentation, the importance of
chemotherapy in the management of ATC cannot be
understated [20]. However, outcomes with chemotherapy
have been disappointing with a few patients with partial
responses and almost none with a complete response after
either mono-therapy or combination therapy [20]. It has
been shown that PTX has some effect on ATC patients but
is not capable to alter the course of the disease [3]. These
data suggest the need for additional therapeutic innova-
tions, such as the encapsulation of drugs in colloidal car-
riers able to an increase the drug content inside the
neoplastic cells [9,12,23,25].
When the biologic activity of free and PTX-NS have been
compared, we observed analogies and differences
between the two systems.
Regarding the biologic effects of PTX-NS two main differ-
ences were observed in respect to free PTX, one in terms of
efficacy and the other of kinetics.
In all the three cellular model tested in this study, the cyto-
toxicity of PTX-NS was higher than that of free PTX. RT
112 cancer cells were the most sensitive to both forms,
whereas MDA MB 231 breast cancer cells were the most
resistant ones.
A different mechanism of transport of PTX-NS in respect
to the free drug can be claimed to explain such differences.
In fact, drug encapsulation in PLGA NS caused a rapid
internalization of the system inside the cells by endocyto-
sis, resulting in a higher cellular uptake. Once inside the
cells, NS escaped the endo-lysosomal pathway and
entered the cytoplasm where they are retained for a longer
time [26].
As a further difference, the kinetic profile of the cytotoxic
activity of PTX-NS was more rapid. PTX-NS significantly
inhibited ARO cells growth after only 2 h of incubation,
whereas the effect of free PTX started after 24 h. These
results can be related to the fast internalization of PTX-NS,
Cytotoxicity of free PTX and PTX-NS in RT 112 cellsFigure 7
Cytotoxicity of free PTX and PTX-NS in RT 112 
cells. RT 112 cells were treated with increasing concentra-
tions (0.1 – 2.0μg/ml) of either free PTX or PTX-NS for 24 
(7A) or 48 (7B) h and cell viability was assessed by the MTS 
assay. Data are expressed as % of viable cells (mean ± SD of 
three separate experiments, each performed in triplicate) 
exposed to PTX in respect to untreated controls. • free PTX 
vs. PTX-NS, *treated vs. not treated •*p < 0.05 ••**p < 0.01
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able inside the cells. On the other hand, also our cou-
marin-6 uptake studies confirmed such a trend.
The goal of our work was to determine the amount of
intracellular (active) PTX. Actually its application was lim-
ited because of the difficulty in determining the intracel-
lular PTX fraction bound to tubulin. To the best of our
knowledge this is the first quantitative demonstration by
HPLC that a NS delivery system may significantly increase
the amount of available PTX inside cells, suggesting that
the greater biological effect of PTX-NS could be due to its
efficient internalization and sustained retention inside the
cells.
Conclusion
In summary, a methodology to produce small and homo-
geneous NS exhibiting high incorporation efficiency of
PTX was described. The incorporation of PTX in PLGA NS
enhanced its cytotoxic activity in three different in vitro
tumor models responsive to PTX, due to a higher cell
uptake of the drug, that we were able to demonstrate.
Even if these data need to be confirmed in other systems
(such as human primary culture or tumor xenografts), this
formulation appears as an interesting delivery system for
PTX in the treatment of cancer.
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